Adagene (ADAG) Stock Forecast, Price Target & Predictions
ADAG Stock Forecast
Adagene stock forecast is as follows: an average price target of $5.00 (represents a 139.23% upside from ADAG’s last price of $2.09) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ADAG Price Target
The average price target for Adagene (ADAG) is $5.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $5.00. This represents a potential 139.23% upside from ADAG's last price of $2.09.
ADAG Analyst Ratings
According to 2 Wall Street analysts, Adagene's rating consensus is 'Buy'. The analyst rating breakdown for ADAG stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Adagene Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | Arthur He | H.C. Wainwright | $5.00 | $2.15 | 132.56% | 139.23% |
| Apr 08, 2024 | Matthew Harrison | Morgan Stanley | $5.00 | $2.83 | 76.68% | 139.23% |
The latest Adagene stock forecast, released on Sep 19, 2024 by Arthur He from H.C. Wainwright, set a price target of $5.00, which represents a 132.56% increase from the stock price at the time of the forecast ($2.15), and a 139.23% increase from ADAG last price ($2.09).
Adagene Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $5.00 | $5.00 |
| Last Closing Price | $2.09 | $2.09 | $2.09 |
| Upside/Downside | -100.00% | 139.23% | 139.23% |
In the current month, the average price target of Adagene stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Adagene's last price of $2.09. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 08, 2024 | Morgan Stanley | Overweight | Overweight | Hold |
Adagene's last stock rating was published by H.C. Wainwright on Sep 19, 2024. The company gave ADAG a "Buy" rating, the same as its previous rate.
Adagene Financial Forecast
Adagene Revenue Forecast
| Mar 27 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $17.50M | - | - | - |
| High Forecast | - | - | - | - | $17.50M | - | - | - |
| Low Forecast | - | - | - | - | $17.50M | - | - | - |
| # Analysts | - | - | - | - | 1 | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Adagene's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ADAG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Adagene EBITDA Forecast
| Mar 27 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $-16.89M | - | - | - |
| High Forecast | - | - | - | - | $-16.89M | - | - | - |
| Low Forecast | - | - | - | - | $-16.89M | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
undefined analysts predict ADAG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Adagene's previous annual EBITDA (undefined) of $NaN.
Adagene Net Income Forecast
| Mar 27 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - |
| Net Income | - | - | - | - | - | - | - | - |
| Avg Forecast | $-41.96M | $-18.11M | $-24.74M | $-39.75M | $-18.55M | $-17.89M | $68.08M | $-11.48M |
| High Forecast | $-41.96M | $-18.11M | $-24.74M | $-39.75M | $-18.55M | $-17.89M | $68.08M | $-11.48M |
| Low Forecast | $-41.96M | $-18.11M | $-24.74M | $-39.75M | $-18.55M | $-17.89M | $68.08M | $-11.48M |
| Surprise % | - | - | - | - | - | - | - | - |
Adagene's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADAG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Adagene SG&A Forecast
| Mar 27 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - |
| SG&A | - | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $61.25M | - | - | - |
| High Forecast | - | - | - | - | $61.25M | - | - | - |
| Low Forecast | - | - | - | - | $61.25M | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - |
Adagene's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ADAG last annual SG&A of $NaN (undefined).
Adagene EPS Forecast
| Mar 27 | Jun 26 | Mar 26 | Sep 25 | Jun 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Avg Forecast | $-0.95 | $-0.41 | $-0.56 | $-0.90 | $-0.42 | $-0.41 | $1.54 | $-0.26 |
| High Forecast | $-0.95 | $-0.41 | $-0.56 | $-0.90 | $-0.42 | $-0.41 | $1.54 | $-0.26 |
| Low Forecast | $-0.95 | $-0.41 | $-0.56 | $-0.90 | $-0.42 | $-0.41 | $1.54 | $-0.26 |
| Surprise % | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Adagene's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADAG previous annual EPS of $NaN (undefined).
Adagene Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.57 | $18.00 | 1046.50% | Buy |
| ANTX | AN2 Therapeutics | $1.30 | $8.75 | 573.08% | Buy |
| MOLN | Molecular Partners | $5.20 | $29.00 | 457.69% | Buy |
| AVTE | Aerovate Therapeutics | $2.66 | $13.00 | 388.72% | Hold |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| ACRV | Acrivon Therapeutics | $6.50 | $21.83 | 235.85% | Buy |
| RZLT | Rezolute | $5.01 | $13.50 | 169.46% | Buy |
| ANAB | AnaptysBio | $20.31 | $52.00 | 156.03% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| ADAG | Adagene | $2.09 | $5.00 | 139.23% | Buy |
| MLYS | Mineralys Therapeutics | $12.60 | $30.00 | 138.10% | Buy |
| JANX | Janux Therapeutics | $48.96 | $61.20 | 25.00% | Buy |